Priyanka S. Rana, James J. Ignatz-Hoover, Chunna Guo, Amber L. Mosley, Ehsan Malek, Yuriy Federov, Drew J. Adams, James J. Driscoll
7 min
Proteasomes generate antigenic peptides that are presented on the tumor surface to cytotoxic T-lymphocytes. Immunoproteasomes are highly specialized proteasome variants that are expressed at higher levels in antigen-presenting cells and contain replacements of the three constitutive proteasome catalytic subunits to generate peptides with a hydrophobic C-terminus that fit within the groove of MHC class I (MHC-I) molecules. A hallmark of cancer is the ability to evade immunosurveillance by disrupting the antigen presentation machinery and downregulating MHC-I antigen presentation. High-throughput screening was performed to identify compound A, a novel molecule that selectively increased immunoproteasome activity and expanded the number and diversity of MHC-I-bound peptides presented on multiple myeloma cells. Compound A increased the presentation of individual MHC-I-bound peptides by >100-fold and unmasked tumor-specific neoantigens on myeloma cells. Global proteomic integral stability assays determined that compound A binds to the proteasome structural subunit PSMA1 and promotes association of the proteasome activator PA28α/β (PSME1/PSME2) with immunoproteasomes. CRISPR/Cas9 silencing of PSMA1, PSME1, or PSME2 as well as treatment with immunoproteasome-specific suicide inhibitors abolished the effects of compound A on antigen presentation. Treatment of multiple myeloma cell lines and patient bone marrow-derived CD138+ cells with compound A increased the anti-myeloma activity of allogenic and autologous T cells. Compound A was well-tolerated in vivo and co-treatment with allogeneic T cells reduced the growth of myeloma xenotransplants in NOD/SCID gamma mice. Taken together, our results demonstrate the paradigm shifting impact of immunoproteasome activators to diversify the antigenic landscape, expand the immunopeptidome, potentiate T-cell-directed therapy, and reveal actionable neoantigens for personalized T-cell immunotherapy.
Cancer cells frequently evade immune surveillance by downregulating antigen presentation machinery and reducing major histocompatibility complex class I (MHC-I) surface expression. This study investigates whether pharmacological activation of immunoproteasomes—specialized proteasome variants that generate peptides optimized for MHC-I binding—can expand the tumor immunopeptidome, unmask hidden neoantigens, and overcome immune evasion to boost T-cell anti-myeloma activity.
The researchers performed high-throughput screening of a targeted small-molecule library using multiple myeloma cells to identify compounds capable of selectively increasing proteasome activity. Hit validation involved fluorogenic peptide assays to measure catalytic activity, global proteomic integral solubility alteration (PISA) assays to identify direct drug targets, CRISPR/Cas9 genetic silencing of target subunits, and mass spectrometry-based immunopeptidomics to sequence MHC-I-bound peptides. Functional consequences were evaluated by co-culturing treated myeloma cells with allogeneic and autologous T cells, measuring target cell apoptosis, and assessing in vivo therapeutic efficacy in a mouse xenograft model.
High-throughput screening identified compound A as a potent and selective immunoproteasome activator. Proteomic profiling revealed that compound A directly binds to the proteasome structural subunit PSMA1 and promotes the association of the regulatory activator complex PA28alpha/beta. This targeted activation increased the presentation of individual MHC-I-bound peptides by more than 100-fold, significantly broadened immunopeptidome diversity, and successfully unmasked tumor-specific neoantigens on multiple myeloma cells. Consequently, treatment with compound A heightened the recognition and cytotoxic efficacy of both allogeneic and autologous T cells against multiple myeloma cell lines and patient-derived primary cells. In vivo administration was well-tolerated and suppressed tumor growth in a murine xenograft model when combined with allogeneic T cells.
These findings establish a paradigm-shifting therapeutic strategy for cancer immunotherapy. Rather than relying solely on immune checkpoint blockade or genetic engineering of T cells, pharmacologically enhancing the intrinsic antigen-processing machinery of tumor cells can diversify their antigenic landscape, making previously invisible cancers vulnerable to T-cell-directed destruction.
Sam: So the drug isn't rewiring the shredder. It's attaching something to the outside that tells the shredder to work harder.
Alex: That's a good way to put it. Once that activator locks into place, it enhances a specific type of cutting activity inside the barrel, driving deeper and more varied cleavage of proteins. The cell starts generating peptide fragments it wasn't producing before — and those new fragments get shipped to the surface.
Sam: Did the researchers confirm that this specific mechanism is actually responsible for the effect? That it's not just a coincidence?
Alex: They did. They used gene editing to silence the structural subunit the drug binds to, and separately silenced the activator components. In both cases, the drug's ability to enhance antigen presentation was completely abolished. Without those specific molecular partners, the compound has no effect at all.
Sam: So the pathway is confirmed. The drug needs those components to work.
Alex: Correct. And the downstream result is measurable. When the researchers used high-resolution mass spectrometry — essentially a very precise chemical inventory of everything displayed on the cell surface — they found a marked increase in both the abundance and diversity of peptide fragments after treatment. The shredder wasn't just working faster. It was processing a wider range of proteins and producing fragment types that had previously been absent.
Sam: So the cancer cell is now posting a much richer set of status updates than before.
Alex: Exactly. And that matters enormously for what comes next — because the immune cells now have far more to read, and far more to react to.
Sam: Which brings us to the actual killing. Did treating the cancer cells this way make them more vulnerable to immune attack in the lab?
Alex: It did. When treated multiple myeloma cells were mixed with cytotoxic T-lymphocytes — the immune cells responsible for killing — the researchers observed roughly a twofold increase in tumor cell death compared to untreated controls. They also tested this using patient bone marrow samples, and saw a similar pattern.
Sam: So it's not just a result in a dish. It held up in material taken from actual patients.
Alex: That's right. And the effect wasn't limited to the cancer cells. When the researchers exposed immune cells directly to the compound, those cells showed reduced expression of a surface marker called PD1. PD1 acts like a brake on immune activity — it's a signal that tells the immune cell to stand down. Lower PD1 means the brake is eased.
Sam: So the drug is working on both sides simultaneously. It's forcing the cancer to expose more targets, and it's releasing the brake on the immune cells doing the hunting.
Alex: That dual effect is precisely what the paper reports. And in mouse models carrying human tumor cells, the compound reduced tumor growth when combined with T cells, and was well tolerated — no significant changes in animal weight or organ systems.
Sam: That's an encouraging safety signal, even if animal models are just a first step.
Alex: Agreed, and the authors are clear about that. The binding site hasn't been resolved at full structural detail yet, and the potential for off-target effects in healthy tissues needs further investigation in living systems. Those are the open questions the paper acknowledges directly.
Sam: So what would the next steps look like?
Alex: Thorough structural characterization — pinpointing exactly where on the proteasome the molecule attaches and confirming it doesn't trigger unintended protein changes in normal cells. Beyond that, the authors suggest this kind of activator could eventually be combined with engineered cellular therapies to tackle what are called "cold tumors" — cancers that carry so few surface markers that current immunotherapies simply can't get a foothold.
Sam: It's a useful reminder that solving immune evasion doesn't always require building a more powerful weapon. Sometimes it's about restoring the machinery the cell already has.
Alex: That's the paper's central contribution. By targeting a specific structural component of the proteasome and recruiting a natural activator, the researchers demonstrated a chemically precise way to expand what cancer cells show on their surface — and in doing so, make them legible again to the immune system.
Sam: The biology was always there. The challenge was finding the right key to unlock it.
Alex: Well put. Thanks for walking through this with me, and thank you all for listening to ResearchPod.